Initiation & Discontinuation
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Initiation & Discontinuation
Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
On-Demand Session
Overview
Focusing on the complexities of initiation, this 2-hour, on-demand session from the 2024 ASAM State of the Art Course explores the critical phases of initiating and discontinuing addiction treatment, highlighting both established best practices and novel ways of implementing treatment interventions. Learners will review common challenges and learn about unique settings for induction.
This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.
- Overcoming Challenges to Initiation of Extended-Release Naltrexone for Treating Opioid Use Disorder: Findings from the HEAL-Initiative NIDA Clinical Trials Network SWIFT Trial
This session will provide an overview of the evidence regarding the effectiveness and safety of XR-naltrexone in the treatment of opioid use disorder. It will address the various challenges that community-based treatment programs face in implementing XR-naltrexone, including barriers related to patient initiation and provider training. Additionally, the presentation will describe a rapid initiation procedure for XR-naltrexone in patients actively using opioids, that has been shown to reduce the time to treatment initiation while maintaining safety and efficacy. This approach aims to improve access to and utilization of this important treatment option within community settings. - Shared Decision-Making and Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: Practical Tools from the SWIFT Trial
This session will cover the findings of the CTN-0097 SWIFT study, which demonstrated the effectiveness and safety of a rapid method of initiation of injection naltrexone among patients with opioid use disorder admitted to inpatient/residential treatment, using mainly non-opioid medications to combat withdrawal and low dose titration of oral naltrexone prior to naltrexone injection. This aims to make initiation of injection naltrexone more feasible within the timeframe of typical short-term inpatient stays. The session will also describe a shared decision-making tool developed for SWIFT to guide discussion between clinicians and patients about choice of medication treatment for opioid use disorder, encouraging initiation of one of the effective medications to reduce risk of relapse and overdose. - Implementation Considerations for Emergency Department-Based Buprenorphine Induction for Opioid Use Disorder
Emergency Departments are increasingly recognized as a unique touchpoint for patient access to treatment for opioid (OUD), although the provision of evidence-based treatments for OUD is underutilized. Innovations in formulations and approach to OUD medications for patients who can be safely transitioned to community partners are evolving, as are strategies to implement programs to provide OUD care. This session will review strategies and rationale for initiating buprenorphine in the emergency department including the use of high dose and injectable formulations, and review data from a recently completed nation-wide study of a 7-day injectable formulation. Strategies for implementing and building a program to evidence-based OUD care will be reviewed as well. - Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies
Most Americans live within 5 miles of a pharmacy, and pharmacists are highly skilled healthcare professionals who provide counseling and dispense life-saving medication—including buprenorphine and methadone--to patients on a daily basis. Pharmacists can administer injectable medications and can be trained to more actively support patients with substance use disorder. Nearly every state has the capacity to provide pharmacist collaborative care models or to adopt pharmacist-led models as a component of much needed expansions of the behavioral health workforce. This session will review key legal and policy structures surrounding pharmacy-based care, present results and implications from a trial of unobserved induction with buprenorphine in pharmacies and consider prospects for delivery models of pharmacy-based methadone for opioid use disorder in community pharmacies.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
DEA Education Requirement
As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Open: 11/01/2024 - 10/01/2027
User Access Closed: 11/01/2027
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Adam Bisaga
Professor of Clinical Psychiatry
Columbia University College of Physicians and Surgeons
Dr. Adam Bisaga is a Professor of Clinical Psychiatry at Columbia University College of Physicians and Surgeons and a Research Scientist at New York State Psychiatric Institute. His NIDA-funded research is focused on development and implementation of new medications and treatment protocols to treat opioid and other substance use disorders. Dr. Bisaga is a member of UN Expert Panel. He contributed to UN and WHO addiction treatment guidances and conducts trainings and addiction treatment program developments internationally. Dr. Bisaga authored more than 100 of peer-reviewed articles, several book chapters, and a book “Overcoming Opioid Addiction“ written for professional and lay audiences. In his commitment to medical education Dr. Bisaga serves as co-director of the SAMHSA-supported “Providers’ Clinical Support System (PCSS)” a national initiative that fosters training of providers and the implementation of effective treatments for opioid use disorders and pain management. His expertise is recognized globally, he is a member of UN Office of Drugs and Crime Expert Panel and a WHO consultant and actively collaborates with United Nations agencies to train healthcare providers and develop international treatment guidelines and programs. Additionally, Dr. Bisaga is at the forefront of integrating technology in addiction healthcare as the Medical Director of Ophelia, a telehealth company specializing in the treatment of opioid use disorder.
Edward Nunes
MD
Dr. Nunes is a Professor of Psychiatry, and Principal Investigator of the Greater New York Node of the National Institute on Drug Abuse (NIDA) clinical Trials Network as well as other NIDA funded studies on behavioral and medication treatments for substance dependence and related psychiatric disorders. Interests and ongoing studies include treatments for cocaine dependence in general, heroin and other opioid dependence, for nicotine dependence in general, and for addicted patients with co-occurring psychiatric disorders including depression, and post-traumatic stress disorder. Types of treatment under study include medication treatments (naltrexone, buprenorphine, mirtazapine) as well as behavioral and psychotherapeutic approaches and computer-delivered treatments. Dr. Nunes also studies the challenges involved in implementing evidence-based treatments for substance use disorders in real-world community-based treatments settings. Dr. Nunes also serves on the American Board of Addiction Medicine, Co-Chair of the Columbia/ New York State Psychiatric Institute's Institutional Review Board, and has been appointed to the National Advisory Council on Drug Abuse.
Kathryn Hawk, MD, MHS
Associate Professor
Yale University
Kathryn Hawk, MD, MHS is an attending physician in the Yale New Haven Hospital Emergency Department and an Associate Professor in the Department of Emergency Medicine, the Yale School of Public Health and the Program in Addiction Medicine. She was a National Institute on Drug Abuse (NIDA) K12 sponsored Drug use, Addiction and HIV Research (DAHRS) Scholar, and is board certified in emergency and addiction medicine. She completed her residency training and research fellowship in the Yale University Department of Emergency Medicine. Her research primarily focuses on the design, testing and implementation of evidence based-care for ED patients with substance use disorders, with an emphasis on initiating medications for opioid and alcohol use disorder in the ED and maximizing effective linkage to ongoing treatment using innovative strategies. Her research on quality improvement and reducing opioid-associated mortality through data linkages, implementation-facilitation ED-initiated buprenorphine for opioid use disorder, initiating treatment for alcohol use disorder in the ED and the dissemination of evidence-based best practices for care of patients with addiction has been funded by NIDA, the Centers for Disease Control and Prevention (CDC), Emergency Medicine Foundation (EMF), Foundation for Opioid Response (FORE), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
Traci Green
PhD, MSc
Dr. Green is Deputy Director of the Boston Medical Center Injury Prevention Center and Associate Professor of Emergency Medicine and Epidemiology at the Warren Alpert School of Medicine at Brown University. She is an epidemiologist whose research focuses on drug abuse, addiction, and injury. She earned a Master of Science in Epidemiology and Biostatistics from McGill University and a PhD in Epidemiology from Yale University. She helped design the ASI-MV®, a real-time illicit and prescription drug abuse surveillance system developed by Inflexxion, Inc. Dr. Green helped co-found www.prescribetoprevent.org, chairs the Drug Overdose Prevention and Rescue Coalition for the Rhode Island Department of Health, and serves as an advisor to the Rhode Island Governor on addiction and overdose. Her research is supported by the Centers for Disease Control and Prevention, the National Institute on Drug Abuse, the Agency for Healthcare Research and Quality, the Patient Centered Outcomes Research Institute, and the Department of Justice.
Credits & Disclosures
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available
- Physicians: 2 Credit(s)
- Nurses & NPs: 2 Nursing Contact Hour(s)
- Pharmacology Hour(s): 1.75 Hour(s)
- PAs: 2 Credit(s)
- Pharmacists: 2 Credit(s)
- Interprofessional Continuing Education: 2 Credit(s)
- Certified Counselors: NBCC Contact Hours Not offered
Note for pharmacists: Not all courses offer CPE Credit. For courses that do offer CPE Credit, pharmacists must claim credit and provide their eProfile ID and Birthdate via the Pharmacist Survey within 30 days of completing the activity. ASAM will not report CPE Credits claimed 30+ days after activity completion to ACPE. ASAM will not report CPE Credits without accurate and complete information. Courses offering CPE Credit will indicate the amount of credit available for pharmacists on the Credits & Disclosure Tab. For any questions or concerns, please e-mail Education@ASAM.org
Maintenance of Certification (MOC)/Continuing Certification Program (CCP)
This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.
- ABA MOCA 2.0®*: 2 Lifelong Learning
- ABIM MOC Points: 2 Medical Knowledge
- ABP MOC: 2 Lifelong Learning & Self-Assessment
- ABS Continuing Certification: 2 Accredited CME | 2 Self-Assessment
Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.
- American Board of Addiction Medicine (ABAM)
- American Board of Preventative Medicine (ABPM)
- American Board of Psychiatry and Neurology (ABPN)
- Royal College of Physicians and Surgeons of Canada (RCPSC)
Certificates for other professions
All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1225.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1224.
MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.
Disclosure Information
In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.
See the attached pdf for a list of disclosures.
Key:
Complete
Next
Failed
Available
Locked